CD44 Isoform status predicts response to treatment with Anti-CD44 antibody in cancer patients

Clinical Cancer Research

Volumn 21, Issue 12, 2015, Pages 2753-2762

  Birzele, Fabian ^a   Voss, Edgar ^b   Nopora, Adam ^b   Honold, Konrad ^b   Heil, Florian ^b   Lohmann, Sabine ^a   Verheul, Henk ^c   Le Tourneau, Christophe ^d   Delord, Jean Pierre ^e   Van Herpen, Carla ^f   Mahalingam, Devalingam ^g   Coveler, Andrew L ^h   Meresse, Valerie ⁱ   Weigand, Stefan ^b   Runza, Valeria ^b   Cannarile, Michael ^b  

^a ROCHE DIAGNOSTICS GMBH   (Germany)

^b ROCHE INNOVATION CENTER MUNICH   (Germany)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d INSTITUT CURIE   (France)

^e INSTITUT CLAUDIUS REGAUD   (France)

^f RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^g University of Texas Health Science Center at San Antonio   (United States)

^h UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

ⁱ F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CD44 ANTIBODY; HERMES ANTIGEN; HYALURONIC ACID; ISOPROTEIN; MONOCLONAL ANTIBODY; RG 7356; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; PROTEIN BINDING; RG7356;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER THERAPY; CELL ADHESION; COLORECTAL CARCINOMA; DRUG DOSE ESCALATION; DRUG RESPONSE; EMBRYO; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; MULTICENTER STUDY (TOPIC); NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PREDICTION; PRIORITY JOURNAL; RNA SEQUENCE; SOLID TUMOR; TUMOR CELL LINE; TUMOR XENOGRAFT; ANIMAL; DISEASE MODEL; DRUG SCREENING; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; GENETICS; HEK293 CELL LINE; MALE; METABOLISM; NEOPLASMS; PATHOLOGY; PROTEIN PROTEIN INTERACTION; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD44; ANTINEOPLASTIC AGENTS; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HUMANS; HYALURONIC ACID; MALE; MICE; NEOPLASMS; PROTEIN BINDING; PROTEIN INTERACTION MAPS; PROTEIN ISOFORMS; TRANSCRIPTION, GENETIC; TRANSFECTION; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84941985213     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-2141     Document Type: Article

References (45)

1. Ringel J, Jesnowski R, Schmidt C, Kohler HJ, Rychly J, Batra SK, et al. CD44 in normal human pancreas and pancreatic carcinoma cell lines. Teratog Carcinog Mutagen 2001;21:97-106.
2. Gotte M, Yip GW. Heparanase, hyaluronan, and CD44 in cancers: A breast carcinoma perspective. Cancer Res 2006;66:10233-7.
3. Liu J, Jiang G. CD44 and hematologic malignancies. Cell Mol Immunol 2006;3:359-65.
4. Yang GH, Fan J, Xu Y, Qiu SJ, Yang XR, Shi GM, et al. Osteopontin combined with CD44, a novel prognostic biomarker for patients with hepatocellular carcinoma undergoing curative resection. Oncologist 2008;13:1155-65.
5. Williams K, Motiani K, Giridhar PV, Kasper S. CD44 integrates signaling in normal stem cell, cancer stem cell and (pre)metastatic niches. Exp BiolMed (Maywood) 2013;238:324-38.
6. Zoller M. CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? Nat Rev Cancer 2011;11:254-67.
7. Bourguignon LY, Zhu D, Zhu H. CD44 isoform-cytoskeleton interaction in oncogenic signaling and tumor progression. Front Biosci 1998;3:d637-49.
8. Miletti-Gonzalez KE, Murphy K, Kumaran MN, Ravindranath AK, Wernyj RP, Kaur S, et al. Identification of function for CD44 intracytoplasmic domain (CD44-ICD): modulation ofmatrix metalloproteinase 9 (MMP-9) transcription via novel promoter response element. J Biol Chem 2012;287:18995-9007.
9. Ishimoto T, Nagano O, Yae T, Tamada M, Motohara T, Oshima H, et al. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. Cancer Cell 2011;19:387-400.
10. Wang SJ, Bourguignon LY. Role of hyaluronan-mediated CD44signaling in head and neck squamous cell carcinoma progression and chemoresistance. Am J Pathol 2011;178:956-63.
11. Weigand S, Herting F, Maisel D, Nopora A, Voss E, Schaab C, et al. Global quantitative phosphoproteome analysis of human tumor xenografts treated with a CD44 antagonist. Cancer Res 2012;72:4329-39.
12. Corbett Th. VF, LoRusso P, Polin L. In vivo methods for screening and preclinical testing: use of rodent solid tumors for drug discovery. In: Teicher BA, Andrews PA, editors. Anticancer drug development guide preclinical screening, clinical trials and approval. Totowa, New Jersey: Humana Press; 1997. p. 75-99.
13. Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nat Methods 2012;9:357-9.
14. Mortazavi A, Williams BA, McCue K, Schaeffer L, Wold B. Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat Methods 2008;5:621-8.
15. Turro E, Su SY, GoncalvesA, Coin LJ, Richardson S, Lewin A. Haplotype and isoform specific expression estimation using multi-mapping RNA-seq reads. Genome Biol 2011;12:R13.
16. The Cancer Genome Atlas Data Portal. 2014; Available from: https://tcgadata. nci.nih.gov/tcga/
17. Anders S, Huber W. Differential expression analysis for sequence count data. Genome Biol 2010;11:R106.
18. Kramer A, Green J, Pollard J Jr, Tugendreich S. Causal analysis approaches in Ingenuity Pathway Analysis. Bioinformatics 2014;30:523-30.
19. Ito T, Williams JD, Fraser D, Phillips AO. Hyaluronan attenuates transforming growth factor-beta1-mediated signaling in renal proximal tubular epithelial cells. Am J Pathol 2004;164:1979-88.
20. Wobus M, Rangwala R, Sheyn I, Hennigan R, Coila B, Lower EE, et al. CD44 associates with EGFR and erbB2 in metastasizing mammary carcinoma cells. Appl Immunohistochem Mol Morphol 2002;10:34-9.
21. Muthukumaran N, Miletti-Gonzalez KE, Ravindranath AK, Rodriguez-Rodriguez L. Tumor necrosis factor-Alpha differentially modulates CD44 expression in ovarian cancer cells. Mol Cancer Res 2006;4:511-20.
22. Gee K, Kozlowski M, Kumar A. Tumor necrosis factor-Alpha induces functionally active hyaluronan-Adhesive CD44 by activating sialidase through p38 mitogen-Activated protein kinase in lipopolysaccharide-stimulated human monocytic cells. J Biol Chem 2003;278:37275-87.
23. Weinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA, Ellrott K, et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet 2013;45:1113-20.
24. Network TCGA. Comprehensive molecular portraits of human breast tumours. Nature 2012;490:61-70.
25. Meyerson MaTCGARN. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012;489:519-25.
26. Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013;497:67-73.
27. Lesley SA, Patten PA, Schultz PG. A genetic approach to the generation of antibodies with enhanced catalytic activities. Proc Natl Acad Sci U S A 1993;90:1160-5.
28. Terpe HJ, Stark H, Prehm P, Gunthert U. Cd44 variant isoforms are preferentially expressed in basal epithelia of nonmalignant human fetal and adult tissues. Histochemistry 1994;101:79-89.
29. Rall CJ, Rustgi AK. CD44 isoform expression in primary and metastatic pancreatic adenocarcinoma. Cancer Res 1995;55:1831-5.
30. Shtivelman E, Bishop JM. Expression of Cd44 is repressed in neuroblastoma-cells. Mol Cell Biol 1991;11:5446-53.
31. Tanabe KK, Ellis LM, Saya H. Expression of Cd44r1 adhesion molecule in colon carcinomas and metastases. Lancet 1993;341:725-6.
32. Olsson E, Honeth G, Bendahl PO, Saal LH, Gruvberger-Saal S, Ringner M, et al. CD44 isoforms are heterogeneously expressed in breast cancer and correlate with tumor subtypes and cancer stem cell markers. Bmc Cancer 2011;11:418.
33. Moll J, Khaldoyanidi S, Sleeman JP, Achtnich M, Preuss I, Ponta H, et al. Two different functions for CD44 proteins in human myelopoiesis. J Clin Invest 1998;102:1024-34.
34. Brown RL, Reinke LM, Damerow MS, Perez D, Chodosh LA, Yang J, et al. CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression. J Clin Invest 2011;121:1064-74.
35. Mima K, Hayashi H, Imai K, Kuroki H, Nakagawa S, Okabe H, et al. High CD44s expression is associated with the EMT expression profile and intrahepatic dissemination of hepatocellular carcinoma after local ablation therapy. J Hepato-Bil-Pan Sci 2013;20:429-34.
36. Biddle A, Gammon L, Fazil B, Mackenzie IC. CD44 staining of cancer stemlike cells is influenced by down-regulation of CD44 variant isoforms and up-regulation of the standard CD44 isoform in the population of cells that have undergone epithelial-To-mesenchymal transition. PLos One 2013;8: e57314.
37. Klingbeil P, Marhaba R, Jung T, Kirmse R, Ludwig T, ZollerM. CD44 variant isoforms promote metastasis formation by a tumor cell-matrix cross-Talk that supports adhesion and apoptosis resistance. Mol Cancer Res 2009;7:168-79.
38. Tamada M, Nagano O, Tateyama S, Ohmura M, Yae T, Ishimoto T, et al. Modulation of glucose metabolism by CD44 contributes to antioxidant status and drug resistance in cancer cells. Cancer Res 2012;72:1438-48.
39. Misra S, Ghatak S, Toole BP. Regulation of MDR1 expression and drug resistance by a positive feedback loop involving hyaluronan, phosphoinositide 3-kinase, and ErbB2. J Biol Chem 2005;280:20310-5.
40. Miletti-Gonzalez KE, Chen S, Muthukumaran N, Saglimbeni GN, Wu X, Yang J, et al. The CD44 receptor interacts with P-glycoprotein to promote cell migration and invasion in cancer. Cancer Res 2005;65:6660-7.
41. Wang YC, Yo YT, Lee HY, Liao YP, Chao TK, Su PH, et al. ALDH1-bright epithelial ovarian cancer cells are associated with CD44 expression, drug resistance, and poor clinical outcome. Am J Pathol 2012;180:1159-69.
42. Shirali AC, Goldstein DR. Activation of the innate immune system by the endogenous ligand hyaluronan. Curr Opin Organ Transplant 2008;13: 20-5.
43. Naor D, Nedvetzki S, Golan I, Melnik L, Faitelson Y. CD44 in cancer. Crit Rev Clin Lab Sci 2002;39:527-79.
44. Banky B, Raso-Barnett L, Barbai T, Timar J, Becsagh P, Raso E. Characteristics of CD44 alternative splice pattern in the course of human colorectal adenocarcinoma progression. Mol Cancer 2012;11:83.
45. Martegani MP, Del Prete F, Gasbarri A, Natali PG, Bartolazzi A. Structural variability of CD44v molecules and reliability of immunodetection of CD44 isoforms using mAbs specific for CD44 variant exon products. Am J Pathol 1999;154:291-300.